Sansure Biotech Inc. (SHA:688289)

Market Cap	8.81B -30.7%
Revenue (ttm)	1.61B -0.2%
Net Income	134.24M -52.3%
EPS	0.23 -52.0%
Shares Out	568.11M
PE Ratio	67.30
Forward PE	35.50
Dividend	0.53 (3.39%)
Ex-Dividend Date	Oct 15, 2026

Volume	2,820,632
Open	15.97
Previous Close	15.97
Day's Range	15.50 - 16.19
52-Week Range	13.40 - 22.94
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers respiratory tract infections, reproductive tract infections, blood-borne infections, gastrointestinal infections, vector-borne diseases and others, DNA/RNA extraction reagents, sample storage reagent, extraction instruments, PCR instruments, mPOCT. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,064
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.64 billion, an increase of 12.58% compared to the previous year's 1.46 billion. Earnings were 198.94 million, a decrease of -27.82%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 27, 2026

Data Sources Report a data error